3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Colorectal Neoplasms
8
Breast Neoplasms
7
Polycythemia Vera
5
Venous Thromboembolism
3
Melanoma
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Tobacco Use Disorder
2
Thrombocythemia, Essential
2
Smoking Cessation
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Neoplastic Cells, Circulating
2
Neoplasms
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Lung Neoplasms
2
Barrett Esophagus
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Tuberous Sclerosis
1
Thromboembolism
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Seizures
1
Salivary Gland Neoplasms
1
Recurrence
1
Primary Myelofibrosis
1
Precancerous Conditions
1
Interventions
Cisplatin
8
Etoposide
6
Paclitaxel
5
Ifosfamide
4
Sunitinib
3
Oxaliplatin
3
Cyclophosphamide
3
Brentuximab Vedotin
3
tremelimumab
2
pembrolizumab
2
etoposide phosphate
2
durvalumab
2
Sirolimus
2
Gemcitabine
2
Everolimus
2
Epirubicin
2
Dexamethasone
2
Carboplatin
2
Bleomycin
2
Bevacizumab
2
tozuleristide
1
rolapitant
1
ribociclib
1
pegfilgrastim
1
pazopanib
1
olaparib
1
fosaprepitant
1
fludarabine phosphate
1
fludarabine
1
cabozantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Germ Cell and Embryonal
×
Aspirin
×
Clear all
NCT06866964
2026-02-02
ASPIRE
Wake Forest University Health Sciences
Phase 2
Recruiting
35 enrolled